Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: BioLife is a life sciences tools provider specializing in patented hypothermic storage and cryopreservation media (HypoThermosol, CryoStor, BloodStor) for cells, tissues, and organs. The company transitioned from contract manufacturing to internal aseptic manufacturing in 2009, achieving ISO 13485:2003 certification in December 2009.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenue | $1,581,600 | $1,322,497 |
| Cost of Product Sales | $1,007,022 | $770,646 |
| Gross Profit | $574,578 | $551,851 |
| Gross Margin | 36.3% | 41.7% |
| Operating Loss | $(2,287,365) | $(2,463,454) |
| Net Loss | $(2,768,352) | $(2,775,117) |
| Cash and Cash Equivalents | $139,151 | $98,724 |
| Working Capital | $535,697 | $95,543 |
| Total Debt (Promissory Notes) | $7,888,127 | $5,063,127 |
| Accumulated Deficit | $(50,211,222) | $(47,442,870) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20% to $1.58 million, driven by a 22% increase in product sales due to new customers and the launch of the BloodStor product line. Licensing revenue declined 44% to $25,000.
- Margin Compression: Gross margin decreased from 41.7% to 36.3%. This was attributed to lower factory utilization during the start-up phase of internal manufacturing operations.
- Operating Expenses: Total operating expenses decreased 5% to $2.86 million. While General and Administrative expenses dropped 22% (due to lower litigation legal fees), Sales and Marketing expenses rose 50% and Manufacturing start-up costs increased 48%.
- Debt Increase: Interest expense surged 71% to $488,013 due to a higher average debt balance. The company drew an additional $2.825 million on its Multi-Draw Term Loan Facilities in 2009.
Outlook, Risks, and Contingencies
- Going Concern: The filing includes a "substantial doubt" regarding the company's ability to continue as a going concern due to an accumulated deficit of approximately $50 million and a history of operating losses. Management relies on continued access to loan facilities from two key shareholders to fund operations for the next nine months.
- Liquidity: Net cash used in operating activities was $2.41 million. The company expects to require additional capital to reach sustainable positive cash flow.
- Legal Proceedings: The company is involved in multiple lawsuits with former executives (John G. Baust and John M. Baust) and their affiliated entities (CPSI, Coraegis) regarding trade secrets, breach of contract, and employment disputes. These cases are in pre-trial discovery.
- Regulatory: While current products do not require FDA pre-market approval, the company anticipates needing approval for future applications in embryo/gamete preservation and organ transplants. The company expects to achieve CE Mark conformity in 2010.
Investor Verification Checklist
- Debt Covenants: Verify the terms of the $7.9 million secured convertible multi-draw term loan facilities, specifically the repayment date (extended to Jan 11, 2011) and the willingness of the two lending shareholders to continue funding.
- Manufacturing Efficiency: Monitor gross margins in subsequent quarters to confirm that internal manufacturing costs stabilize as factory utilization increases.
- Customer Concentration: Review the dependency on top customers, as two customers accounted for 31% of total product sales in 2009.
- Litigation Exposure: Assess the potential financial impact of ongoing lawsuits with former executives, which could result in significant damages or injunctions.
- Cash Burn Rate: Evaluate the runway provided by current cash ($139k) and remaining loan availability ($1.1 million) against the monthly operating burn rate.